| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
28,836 |
24,887 |
$1.84M |
| 80053 |
Comprehensive metabolic panel |
19,474 |
16,348 |
$1.73M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
6,256 |
5,402 |
$832K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
8,270 |
7,179 |
$803K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
924 |
505 |
$453K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,714 |
4,434 |
$406K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,802 |
1,696 |
$373K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,341 |
4,417 |
$336K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,527 |
3,135 |
$291K |
| 81025 |
|
11,703 |
10,365 |
$290K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
20,829 |
18,110 |
$275K |
| 36415 |
Collection of venous blood by venipuncture |
5,009 |
3,504 |
$245K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,038 |
4,331 |
$236K |
| 84702 |
|
3,167 |
2,611 |
$236K |
| 87210 |
|
2,810 |
2,520 |
$234K |
| 86900 |
|
2,305 |
2,056 |
$226K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,856 |
1,705 |
$192K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,177 |
1,055 |
$183K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
5,952 |
4,898 |
$181K |
| 81002 |
|
1,408 |
1,160 |
$178K |
| 81001 |
|
7,472 |
6,666 |
$177K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,910 |
2,748 |
$173K |
| 82962 |
|
4,859 |
2,169 |
$156K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,757 |
2,618 |
$150K |
| 71046 |
Radiologic examination, chest; 2 views |
6,208 |
5,526 |
$142K |
| 81003 |
|
8,282 |
7,302 |
$142K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,020 |
1,786 |
$139K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,482 |
1,283 |
$132K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
2,290 |
1,927 |
$116K |
| 87081 |
|
1,210 |
1,104 |
$107K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
953 |
830 |
$106K |
| 77066 |
Tomosynthesis, mammo |
870 |
825 |
$104K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,739 |
2,457 |
$98K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,895 |
1,594 |
$97K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,019 |
1,439 |
$94K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,632 |
2,919 |
$92K |
| 84112 |
|
250 |
201 |
$78K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
3,250 |
2,903 |
$65K |
| 76642 |
|
2,308 |
1,830 |
$62K |
| 72100 |
|
1,335 |
1,191 |
$60K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,063 |
7,148 |
$59K |
| 73562 |
|
892 |
761 |
$57K |
| 73630 |
|
852 |
683 |
$57K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
22,077 |
18,206 |
$50K |
| 93971 |
|
387 |
329 |
$48K |
| 71045 |
Radiologic examination, chest; single view |
3,630 |
3,130 |
$48K |
| 73610 |
|
422 |
362 |
$44K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,028 |
696 |
$44K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
452 |
382 |
$35K |
| 73030 |
|
555 |
487 |
$35K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,595 |
2,345 |
$35K |
| 77065 |
Tomosynthesis, mammo |
736 |
638 |
$34K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
900 |
796 |
$33K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,566 |
1,358 |
$33K |
| 86850 |
|
927 |
820 |
$33K |
| 85018 |
|
1,297 |
1,013 |
$32K |
| 73130 |
|
326 |
270 |
$32K |
| 87807 |
|
329 |
299 |
$32K |
| 87186 |
|
623 |
542 |
$31K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
251 |
218 |
$29K |
| 96376 |
|
1,207 |
777 |
$28K |
| 87040 |
|
1,139 |
659 |
$26K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
304 |
265 |
$23K |
| 85027 |
|
3,681 |
3,131 |
$19K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
6,532 |
4,960 |
$18K |
| 72040 |
|
234 |
196 |
$17K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
482 |
367 |
$15K |
| G0378 |
Hospital observation service, per hour |
3,531 |
1,536 |
$14K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,259 |
1,151 |
$13K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
904 |
301 |
$11K |
| 59025 |
Fetal non-stress test |
3,745 |
2,739 |
$11K |
| 74018 |
|
155 |
131 |
$11K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
503 |
446 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
783 |
708 |
$9K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,172 |
594 |
$9K |
| 76830 |
Ultrasound, transvaginal |
359 |
316 |
$8K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
9,461 |
7,709 |
$8K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,178 |
1,628 |
$8K |
| 97161 |
|
939 |
788 |
$8K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
7,426 |
6,470 |
$8K |
| 73110 |
|
59 |
49 |
$7K |
| 83735 |
|
4,182 |
3,482 |
$7K |
| 84484 |
|
5,662 |
3,683 |
$7K |
| 85379 |
|
1,112 |
1,006 |
$6K |
| 82565 |
|
92 |
79 |
$6K |
| 81015 |
|
644 |
556 |
$6K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
3,692 |
2,774 |
$5K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
111 |
12 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
4,298 |
3,262 |
$4K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
231 |
217 |
$4K |
| 86140 |
|
848 |
751 |
$4K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
31 |
29 |
$3K |
| 87634 |
|
191 |
181 |
$3K |
| 85610 |
|
1,346 |
1,160 |
$3K |
| 87641 |
|
282 |
270 |
$3K |
| 82731 |
|
25 |
24 |
$3K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
13 |
13 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,208 |
2,863 |
$3K |
| 80050 |
General health panel |
32 |
26 |
$3K |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
548 |
369 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,868 |
2,276 |
$2K |
| 74022 |
|
210 |
180 |
$2K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
182 |
108 |
$2K |
| 94760 |
|
1,031 |
790 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,034 |
2,508 |
$2K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
73 |
55 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
7,414 |
6,207 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
198 |
183 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
7,215 |
5,957 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
2,031 |
1,313 |
$2K |
| 87070 |
|
14 |
14 |
$1K |
| 88307 |
|
212 |
184 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,055 |
3,649 |
$1K |
| 73502 |
|
70 |
65 |
$1K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
499 |
445 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,587 |
4,092 |
$1K |
| 99215 |
Prolong outpt/office vis |
49 |
40 |
$1K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,596 |
2,265 |
$996.28 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,865 |
1,397 |
$825.61 |
| 97162 |
|
53 |
50 |
$819.51 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
104 |
92 |
$775.78 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
13 |
13 |
$747.52 |
| 84443 |
Thyroid stimulating hormone (TSH) |
203 |
187 |
$721.18 |
| 93975 |
|
138 |
128 |
$651.24 |
| 84550 |
|
149 |
127 |
$550.70 |
| 97597 |
|
23 |
15 |
$506.57 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
37 |
26 |
$482.40 |
| 82077 |
|
104 |
93 |
$479.97 |
| 87077 |
|
16 |
12 |
$453.41 |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
198 |
179 |
$449.00 |
| 97165 |
|
196 |
184 |
$447.56 |
| 97535 |
Self-care/home management training, each 15 minutes |
222 |
119 |
$414.64 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
1,333 |
1,097 |
$393.74 |
| 83605 |
|
2,251 |
1,831 |
$370.64 |
| 83690 |
|
7,612 |
6,568 |
$330.34 |
| 76801 |
|
248 |
233 |
$281.96 |
| 84132 |
|
28 |
24 |
$270.58 |
| 83880 |
|
493 |
411 |
$237.44 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
685 |
585 |
$214.55 |
| 94761 |
|
367 |
254 |
$154.00 |
| 94762 |
|
285 |
238 |
$129.18 |
| 84145 |
|
561 |
498 |
$104.88 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
785 |
751 |
$58.54 |
| 85730 |
|
229 |
213 |
$56.48 |
| 80061 |
Lipid panel |
123 |
112 |
$37.62 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,027 |
2,726 |
$18.61 |
| J3490 |
Unclassified drugs |
2,287 |
1,627 |
$14.80 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,367 |
1,172 |
$5.12 |
| 86901 |
|
2,304 |
2,055 |
$3.80 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
178 |
160 |
$2.61 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
296 |
268 |
$2.01 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
731 |
634 |
$0.00 |
| 87088 |
|
281 |
259 |
$0.00 |
| J2372 |
Injection, phenylephrine hydrochloride (biorphen), 20 micrograms |
44 |
40 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
303 |
261 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
703 |
581 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
120 |
96 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
90 |
78 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
46 |
40 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
21 |
16 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
16 |
12 |
$0.00 |
| 85652 |
|
33 |
25 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
96 |
85 |
$0.00 |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
19 |
18 |
$0.00 |
| 88304 |
|
13 |
12 |
$0.00 |
| 86141 |
|
13 |
13 |
$0.00 |
| 84703 |
|
14 |
12 |
$0.00 |
| 83615 |
|
29 |
26 |
$0.00 |
| 87205 |
|
31 |
27 |
$0.00 |
| 94664 |
|
160 |
139 |
$0.00 |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
167 |
119 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
13 |
12 |
$0.00 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
760 |
685 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
36 |
25 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
381 |
329 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
58 |
50 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
88 |
72 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
61 |
40 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
45 |
41 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
38 |
38 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
161 |
151 |
$0.00 |
| 84156 |
|
15 |
13 |
$0.00 |
| 90715 |
|
14 |
12 |
$0.00 |
| 82570 |
|
44 |
37 |
$0.00 |
| C1776 |
Joint device (implantable) |
44 |
40 |
$0.00 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
56 |
55 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
17 |
13 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
44 |
27 |
$0.00 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
19 |
18 |
$0.00 |
| Q0245 |
Injection, bamlanivimab and etesevimab, 2100 mg |
37 |
15 |
$0.00 |
| J0670 |
Injection, mepivacaine hydrochloride, per 10 ml |
14 |
13 |
$0.00 |